A Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy of Xolair in an Allergen Bronchoprovocation Study in Asthmatic Populations Defined by Serum IgE Concentrations.

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy of Xolair in an Allergen Bronchoprovocation Study in Asthmatic Populations Defined by Serum IgE Concentrations.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 11 Feb 2011 Trial phase changed from II to IV as reported by ClinicalTrials.gov.
    • 11 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Feb 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top